Boston Biomedical is expanding! We recently moved into state-of-the-art facilities in Cambridge, Massachusetts, and are growing our team of scientists, researchers, and other innovators who share our vision of innovation for life! Follow the links below to learn more about:
BBI608 is the most clinically advanced candidate in Boston Biomedical’s cancer stem cell (CSC) pathway inhibitor program. This first-in-class, orally-administered small molecule blocks CSC self-renewal and induces cell death in CSCs as well as non-stem cancer cells.
Tell me more